公司介绍

 

五险一金年底双薪绩效奖金免费班车补充医疗保险员工旅游

诺和诺德(中国)制药有限公司天津生产厂

 

诺和诺德公司是一家致力于维护人类健康的跨国企业,88年来一直以其创新的理念居于糖尿病治疗领域的先导地位。同时,公司在血友病治疗,生长激素疗法以及荷尔蒙替代疗法等领域也居世界领先地位。

 

诺和诺德(中国)制药有限公司天津生产厂是诺和诺德公司的战略性生产基地,面向全球以及中国市场供应胰岛素耐用注射器械,胰岛素成品以及胰岛素注射用针头成品。天津生产厂位于天津经济技术开发区,占地面积约为128,000平方米,截止到2011年底,员工总数为830多名。

 

天津生产厂最初于1995年成立,于2002年在天津经济技术开发区扩建并于2003年正式落成投产,开始向全球以及中国市场供应糖尿病成品,2008年底,诺和诺德总部再次斥资筹建胰岛素生产设施以实现对中国糖尿病患者的长期承诺并满足日益增长的市场需求。

 

诺和诺德(中国)制药有限公司天津生产厂现已发展成为诺和诺德公司全球唯一的胰岛素耐用注射器械供应商,以及丹麦以外全球最大的胰岛素制剂与灌装生产基地。

 

作为亚太地区诺和诺德公司首要的糖尿病成品供应基地,天津生产厂正在不断的发展壮大,其战略地位也在显著提升。天津生产厂对其产品有着严格的质量要求,质量管理体系严格遵循中国及国际上相关法律法规,耐用注射器械相关生产已获得ISO9001ISO13485国际体系认证,并已通过包含美国食品药品管理局(FDA)在内的众多国际审核,胰岛素相关生产也已获得欧盟GMP认证。与此同时,公司总部也对天津生产厂的发展提供了大量的技术支持和资金投入,以保证其产品的高质量性。

 

诺和诺德公司1994年进入中国,截至到2010年底公司在华总投资额已将近4亿美元,约合26亿元人民币。在诺和诺德,我们始终秉承兼顾经济责任、社会责任以及环境责任的理念来经营我们的业务。我们将不断的发展和贡献以实现对中国社会的承诺,致力于改善中国糖尿病患者的生活质量。

 

 

Novo Nordisk (China) Pharmaceuticals Co., Ltd. (Tianjin Plant)

 

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

 

Novo Nordisk (China) Pharmaceuticals Co., Ltd. (Tianjin Plant) is a strategic manufacturing site of Novo Nordisk. It supplies to both global and domestic market with durable devices for insulin injection, finished products of insulin and needles for insulin injection. Tianjin plant locates in Tianjin Economic-Technological Development Area (TEDA). It covers an area of 128,000 square metres in TEDA and employs approximately 830 employees.

 

Tianjin Plant was established in 1995. The plant was expanded in TEDA in 2002 and started to supply diabetes finished products to the market in 2003. At the end of 2008, Novo Nordisk decided to invest again for building up insulin production facilities at Tianjin Plant in order to realize the long-term commitment to Chinese people with diabetes and satisfy the growing Chinese market.

 

Novo Nordisk (China) Pharmaceuticals Co., Ltd. (Tianjin Plant) has become the single manufacturer of Novo Nordisk to provide durable devices to the global market and the biggest production site of Novo Nordisk outside Denmark for insulin formulation and filling.

 

As the primary strategic manufacturer of Novo Nordisk in Asia Pacific area to supply diabetes finished products, Tianjin Plant is growing very fast and its strategic position is obviously being promoted. Tianjin Plant has strict quality requirements on the products. Quality management system of Tianjin Plant precisely conforms to the relevant Chinese and international regulations. Durable devices production has got the certification of ISO9001 and ISO13485 and passed the inspection of US FDA and other international authorities. EU GMP certificate has also been granted to the insulin production. Novo Nordisk headquarters in Denmark has been contributing a lot on the development of Tianjin Plant both technically and economically to ensure the high quality of its products.

 

Since 1994 when Novo Nordisk came to China, the total investment of the company in China has achieved approximately 400 million USD (2.6 billion CNY) until the end of 2010. At Novo Nordisk, we strive to do business in a financially, socially and environmentally responsible way and we will be developing and contributing continuously for the commitment to the Chinese society and improving the life quality of people with diabetes in China.

招聘职位

 

  • 全部职位
  • 技工/操作工
  • 生物/制药/医疗器械

类别名称

    联系方式

    地址:天津经济技术开发区南海路99号
    邮政编码:300457
    传 真:
    分享你关心的人吧!